CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
暂无分享,去创建一个
F. Zhan | K. Anderson | N. Munshi | P. Richardson | A. Kung | Y. Tai | Y. Tai | I. Ghobrial | L. Wu | W. Senapedis | Y. Gu | M. Cea | M. Reagan | Y. Calle | Y. Landesman | S. Shacham | C. Acharya | M. Zhong | Lizi Wu | T. Kashyap | M. Kauffman | Yu-mei Gu | S. Schey | A. Munshi | A. Cagnetta | D. Tannenbaum | J. Saint-Martin | K. Anderson | Nikhil C. Munshi | L. Wu | Aditya Munshi | Daniel Tannenbaum
[1] Yuh Min Chook,et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. , 2012, Blood.
[2] N. Grishin,et al. NESdb: a database of NES-containing CRM1 cargoes , 2012, Molecular biology of the cell.
[3] Guido Marcucci,et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. , 2012, Blood.
[4] Michael A. Sellitto,et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. , 2012, Blood.
[5] A T Look,et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells , 2012, Leukemia.
[6] D. Sullivan,et al. Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.
[7] S. Mousses,et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. , 2012, Cancer research.
[8] M. Oren,et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. , 2012, Molecular cell.
[9] B. Henderson,et al. Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome , 2012, The Journal of Biological Chemistry.
[10] Y. Pekarsky,et al. NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.
[11] Donald W Kufe,et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. , 2011, Blood.
[12] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[13] V. Leaner,et al. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. , 2011, Biochimica et biophysica acta.
[14] P. Koty,et al. p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.
[15] P. Silver,et al. Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain , 2011, Molecular Biology of the Cell.
[16] T. Marafioti,et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. , 2011, Blood.
[17] K. Anderson,et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.
[18] Li-wei Wang,et al. Prognostic value of CRM1 in pancreas cancer. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.
[19] Li-wei Wang,et al. Prognostic value of CRM1in pancreas cancer , 2009 .
[20] Peter Washausen,et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. , 2009, Cancer research.
[21] M. Birrer,et al. The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation , 2009, International journal of cancer.
[22] S. Mutka,et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.
[23] D. Sullivan,et al. CRM1-mediated nuclear export of proteins and drug resistance in cancer. , 2008, Current medicinal chemistry.
[24] N. Munshi,et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.
[25] Carsten Denkert,et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer , 2008, Cancer.
[26] S. Hanai,et al. Inhibition of Crm1–p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation , 2007, Nature Cell Biology.
[27] N. Munshi,et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. , 2007, Blood.
[28] Kenneth C. Anderson,et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.
[29] J. Miguel,et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals , 2007, Leukemia.
[30] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[31] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[32] David R Williams,et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.
[33] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[34] T. Mak,et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.
[35] N. Munshi,et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.
[36] Y. Toyama,et al. DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.
[37] Hao Jiang,et al. Triple Layer Control: Phosphorylation, Acetylation and Ubiquitination of FOXO Proteins , 2005, Cell cycle.
[38] S. Bicciato,et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma , 2005, Oncogene.
[39] K. Toh,et al. RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis , 2004, The Journal of experimental medicine.
[40] R. Jove,et al. Human topoisomerase IIα nuclear export is mediated by two CRM-1-dependent nuclear export signals , 2004, Journal of Cell Science.
[41] A. Grinberg,et al. Visualization of Myc/Max/Mad Family Dimers and the Competition for Dimerization in Living Cells , 2004, Molecular and Cellular Biology.
[42] K. Tarte,et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. , 2004, Blood.
[43] J. Cleveland,et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.
[44] Hiroshi Takayanagi,et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.
[45] Minoru Yoshida,et al. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes , 2000 .
[46] E. Newlands,et al. Phase I trial of elactocin. , 1996, British Journal of Cancer.
[47] K. Sikora,et al. Leukemia , 1984, British Journal of Cancer.
[48] Y. Dong,et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. , 2009, Oncology reports.
[49] N. Kudo,et al. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.